Terumo Announces All Dexcom G6 CGM System Users on Insulin Therapy to be Covered by Insurance in Japan

This addition of a new reimbursement category will allow more people the opportunity for better diabetes management

TOKYO, JAPAN – December 1, 2022 – Terumo Corporation (TSE: 4543) today announced that the reimbursement coverage within the Japanese medical insurance system has expanded for the Dexcom G6 CGM System, as of December 1, 2022. With the newly added category of “C150”, a wider group of people with diabetes will be eligible to receive reimbursement using the Dexcom G6 CGM System in Japan.

The Dexcom G6 CGM System is a real-time glucose monitoring system developed and manufactured by Dexcom Inc., and Terumo has been marketing the product in Japan since 2021. A wearable sensor is attached to the user’s abdomen, and glucose measurements are automatically transmitted every five minutes to a monitor or a smart device with a dedicated application installed. With the monitor and/or app, users can check their real-time glucose values and trends with a visualized graph. The Dexcom G6 CGM System also has a function that notifies users when glucose measurements fall outside the pre-set target range and alerts the user when it predicts that hypoglycemia will occur in 20 minutes. Compared to the traditional blood glucose meter, the Dexcom G6 CGM System provides abundant data such as glucose level trends, which can help users manage their diabetes more effectively. Globally, there are more than 1.25 million Dexcom G6 CGM System users.

In the two reimbursement categories the Dexcom G6 CGM System has been previously covered, those that were eligible to be reimbursed were limited to a person with type 1 diabetes, or a person with type 2 diabetes with the conditions of unstable glycemic control. In addition, hospitals had to apply for eligibility to prescribe the Dexcom G6 CGM System and receive reimbursement, and only facilities that meet a specific criteria were able to submit application.

The newly added "C150" category covers all people who undergo insulin self-injection at least once a day, regardless of the type of diabetes, to use the Dexcom G6 CGM System under the Japanese medical insurance program. Furthermore, there is no need for hospitals to submit for eligibility since with the new category, all facilities can receive reimbursement. 

Terumo will continue to contribute to advancing healthcare and enhancing patients' quality of life, based on its Corporate Mission of "Contributing to Society Through Healthcare”.